{"id":"NCT00536263","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)","officialTitle":"An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2007-09-27","resultsPosted":"2010-12-21","lastUpdate":"2017-04-07"},"enrollment":671,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis B, Chronic"],"interventions":[{"type":"DRUG","name":"pegylated interferon alpha-2b","otherNames":[]},{"type":"DRUG","name":"pegylated interferon alpha-2b","otherNames":[]},{"type":"DRUG","name":"pegylated interferon alpha-2b","otherNames":[]}],"arms":[{"label":"PEG 1.0 mcg/kg weekly (QW) * 24 weeks","type":"ACTIVE_COMPARATOR"},{"label":"PEG 1.5 mcg/kg QW * 24 wks","type":"EXPERIMENTAL"},{"label":"PEG 1.5 mcg/kg QW * 48 wks","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the approved dosage, which is PegIntron 1.0 microgram (mcg)/kg given once a week for 24 weeks. This study compares dosages of (1) 1.5 mcg/kg once a week for 24 weeks and (2) 1.5 mcg/kg once a week for 48 weeks with the approved dosage. All subjects are followed for 24 weeks after their treatment ends.","primaryOutcome":{"measure":"Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss","timeFrame":"24 weeks after end of treatment (EOT)","effectByArm":[{"arm":"PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks","deltaMin":39,"sd":null},{"arm":"PEG 1.5 mcg/kg QW * 24 Weeks","deltaMin":40,"sd":null},{"arm":"PEG 1.5 mcg/kg QW * 48 Weeks","deltaMin":70,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.860"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25200354"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":225},"commonTop":["PYREXIA","MYALGIA","HEADACHE","FATIGUE","ALOPECIA"]}}